#USA #Chicago #Vaniam Group #Bio Ascend #iwNHL

Bio Ascend Enhances Scientific Initiatives in Oncology

In a significant move within the field of hematologic oncology, Bio Ascend™, a company under the Vaniam Group™, has officially assumed leadership of the renowned iwNHL™ and iwMyeloma™ workshops. This strategic transition comes as a result of extensive collaboration with World Health Communications, ensuring that the invaluable legacy and leadership of the workshops continue to thrive.

A New Chapter in Hematologic Oncology

The iwNHL and iwMyeloma workshops have long been pivotal platforms for scientific dialogue and innovation in the study of non-Hodgkin lymphoma and multiple myeloma. On June 4, 2026, Vaniam Group and World Health Communications announced that Bio Ascend would lead these workshops, following a sustained commitment to scientific exchange and collaboration.

Deanna B. van Gestel, the CEO of Vaniam Group, expressed enthusiasm about the transition, stating, "iwNHL and iwMyeloma are defining forums in hematologic oncology. Our role is to build on that foundation while leading the next phase of growth for these forums." This affirmation highlights Bio Ascend's dedication to advancing knowledge and innovation in the field.

Purposeful Leadership for Future Developments

Bio Ascend is stepping into its new role with a clear plan in sight. The company is committed to the organization, delivery, and ongoing evolution of these workshops, collaborating closely with Dr. Stuart W. G. Smith, the founder of World Health Communications, and other leading scientific figures. This leadership team aims to ensure that the workshops remain relevant and impactful for the global medical community.

Dr. Smith emphasized the importance of maintaining meaningful scientific exchange within these forums. "I'm pleased to continue working alongside Vaniam Group and Bio Ascend as they take on leadership in supporting and advancing these International Workshops, ensuring their continued relevance and impact for the global community," he stated.

Expanding Global Reach

Kraig Steubing, EVP of Vaniam Group, also commented on the future of iwNHL and iwMyeloma, stating, "These workshops are defined by the strength of the communities they bring together. Our focus is expanding their reach globally while preserving what makes them essential to the field." This vision indicates a robust strategy focusing on inclusivity and accessibility in the field of hematologic education.

About Bio Ascend and Vaniam Group

Bio Ascend is dedicated to enhancing medical education in various challenging disease areas including oncology, hematology, cell therapy, rare diseases, and more. The company designs educational activities that are not only scientifically rigorous but also clinically relevant, ensuring the educational programs align with the evolving landscape of medicine.

As a wholly owned subsidiary of Vaniam Group, Bio Ascend benefits from the latter’s extensive experience in the oncology sector, having been established in 2007. Vaniam Group's mission is to empower better decision-making within biopharma teams, clinicians, and ultimately, patients, all while maintaining its status as a certified Women's Business Enterprise (WBENC) and achieving EcoVadis Platinum rating for sustainability.

World Health Communications, the organization that previously led these workshops, has been a crucial player in facilitating high-impact scientific exchanges in hematologic oncology, enabling the collaboration of clinicians, researchers, and industry professionals. Under the astute guidance of Bio Ascend, the legacy of iwNHL and iwMyeloma is set to reach new heights, promising a significant impact on future oncological practices and education.

In conclusion, Bio Ascend's leadership of the iwNHL and iwMyeloma workshops marks an important milestone for the field of hematologic oncology, signaling a future of enhanced collaboration, education, and treatment methodologies that will benefit healthcare providers and patients alike.